| pubmed-article:3327149 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3327149 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3327149 | lifeskim:mentions | umls-concept:C0275804 | lld:lifeskim |
| pubmed-article:3327149 | lifeskim:mentions | umls-concept:C0014806 | lld:lifeskim |
| pubmed-article:3327149 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:3327149 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:3327149 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:3327149 | lifeskim:mentions | umls-concept:C0724001 | lld:lifeskim |
| pubmed-article:3327149 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:3327149 | pubmed:dateCreated | 1988-4-18 | lld:pubmed |
| pubmed-article:3327149 | pubmed:abstractText | A multicenter clinical trial on the efficacy and safety of a twice-a-day administration of erythromycin base was performed on 261 adolescent or adult patients with acute tonsillitis. The patients were randomized for each doctor separately into q.i.d. (4 x 250 mg) and b.i.d. (2 x 500 mg) groups. Throat swabs were cultured for group A beta-haemolytic streptococci before the treatment and, in positive cases (100 patients), 2-3 days after completing the treatment of at least 7 days. No significant difference in the efficacy between the two regimens was observed as judged by clinical evaluation or bacteriological examination. About 90% of patients were completely healed by both criteria in both treatment groups. Side-effects were reported in 40 and 44% respectively, in the treatment groups. However, only 9/244 (3.7%) had to stop the treatment because of side-effects. Six of these belonged to the b.i.d. group and 3 to the q.i.d. group. This difference is not statistically significant (p greater than or equal to 0.05). Our results suggest that twice-a-day regimen of erythromycin base is an effective and well-tolerated treatment of streptococcal tonsillitis. | lld:pubmed |
| pubmed-article:3327149 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3327149 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3327149 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3327149 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3327149 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3327149 | pubmed:issn | 0036-5548 | lld:pubmed |
| pubmed-article:3327149 | pubmed:author | pubmed-author:ValtonenVV | lld:pubmed |
| pubmed-article:3327149 | pubmed:author | pubmed-author:HoviTT | lld:pubmed |
| pubmed-article:3327149 | pubmed:author | pubmed-author:SvahnTT | lld:pubmed |
| pubmed-article:3327149 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3327149 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:3327149 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3327149 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3327149 | pubmed:pagination | 661-6 | lld:pubmed |
| pubmed-article:3327149 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:meshHeading | pubmed-meshheading:3327149-... | lld:pubmed |
| pubmed-article:3327149 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3327149 | pubmed:articleTitle | Twice-a-day regimen of erythromycin base is effective in the treatment of acute streptococcal tonsillitis. | lld:pubmed |
| pubmed-article:3327149 | pubmed:affiliation | Department of Virology, University of Helsinki, Finland. | lld:pubmed |
| pubmed-article:3327149 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3327149 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3327149 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:3327149 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3327149 | lld:pubmed |
